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Reversal of Hypolipidemia in Chronic Hepatitis C
Patients After Successful Antiviral Therapy
Yuan-Hung Kuo,1 Tang-Wei Chuang,2 Chao-Hung Hung,1* Chien-Hung Chen,1
Jing-Houng Wang,1 Tsung-Hui Hu,1 Sheng-Nan Lu,1 Chuan-Mo Lee1
Background/Purpose: Chronic infection with the hepatitis C virus (HCV) is associated with impaired
lipid metabolism. The aim of this study was to determine the impact of antiviral response on the serial
change of serum lipids in chronic HCV patients.
Methods: A total of 165 consecutive patients with HCV infection were prospectively enrolled. Serum total
cholesterol (TC) and triglyceride (TG) levels in these subjects were compared with age, sex and body 
mass index-matched healthy individuals and 55 patients with chronic infection with hepatitis B virus
(HBV). Serum lipid levels were measured in 143 patients with chronic HCV infection receiving pegylated
interferon plus ribavirin therapy at baseline, at the end of treatment, and at week 24 after the end of 
treatment.
Results: Patients with chronic HCV infection had significantly lower total TC and TG levels than normal con-
trols (both p<0.001). Serum TC levels were lower in HCV patients than in those infected with HBV (p<0.001).
Pretreatment serum lipid levels were not independent factors associated with sustained virological response
(SVR). Among patients achieving a SVR, serum TC and TG levels significantly increased from 165 ± 30 mg/dL
and 100 ± 47 mg/dL at baseline to 191 ± 36 mg/dL (p < 0.001) and 116 ± 77 mg/dL (p = 0.029) at week 24
posttreatment, whereas no evident change in lipid profile occurred in the non-SVR group.
Conclusion: Our data suggest that chronic HCV infection is associated with hypocholesterolemia and 
hypotriglyceridemia, which can be reversed by successful eradication of HCV. The clinical significance of
hypolipidemia reversal among SVR patients, such as the risk of coronary artery or cerebral vascular disease,
should be further investigated.
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Chronic infection with hepatitis C virus (HCV) is
the leading cause of liver cirrhosis and hepato-
cellular carcinoma, with an estimated 200 million
chronic carriers worldwide.1–3 Aside from the es-
tablished consequence of liver injury, chronic HCV
infection is also attributed to various extrahepatic
manifestations.4,5 Recently, much attention has
been drawn to its relationship with metabolic
disorders. Based on large-scale epidemiological
studies, there is strong evidence of the associations
between HCV infection and elevated blood sugar,
as well as lipid metabolism.6–11 Ongoing research
into the HCV life cycle has demonstrated a strong
interaction between the virus and intracellular
lipids, suggesting that host lipids play an impor-
tant role in viral replication.12 In addition, the
binding of HCV to lipoprotein in plasma and the
association between HCV infection and hypo-
betalipoproteinemia have been reported.9,13–16
Interferon (IFN) based therapy has been widely
used to eradicate HCV and prevent the progress
of liver disease. At present, combination therapy
of pegylated (PEG)-IFN and oral ribavirin is the
current standard treatment for chronic HCV in-
fection.17,18 Previous studies have shown that lipid
factors such as hepatic steatosis and plasma lipid
profiles may serve as predictors of therapeutic re-
sponses in patients with chronic hepatitis C, but
this theory is controversial.19–22 The aim of our
study was to investigate serum cholesterol and
triglyceride levels in patients with chronic HCV
infection compared with normal healthy controls
or those infected with chronic hepatitis B. We 
determined the association of serum lipid levels
and the response to PEG-IFN plus ribavirin ther-
apy in chronic hepatitis C patients. Furthermore,
we studied the impact of treatment response on
the serial changes of serum lipid levels after PEG-
IFN plus ribavirin therapy.
Patients and Methods
Patients
Between Jan 2005 and Dec 2007, a total of 165
consecutive chronic hepatitis C patients who were
regularly followed at our outpatient clinics were
prospectively enrolled. Chronic HCV infection
was defined as positivity of antibody to HCV 
and serum HCV RNA for more than 6 months.
Patients with co-infection of hepatitis B virus
(HBV) or human immunodeficiency virus, excess
alcohol consumption or drug abuse, previous
history of IFN based therapy, current treatment
with anti-lipid drugs, and liver disease of other eti-
ologies such as autoimmune liver disease, hemo-
chromatosis, and Wilson’s disease were excluded.
Baseline data including age, sex, pretreatment
body mass index (BMI), serum fasting glucose,
triglyceride, total cholesterol levels, aspartate trans-
aminase (AST), alanine transaminase (ALT), and
complete blood count were collected. BMI was
calculated as weight in kilograms divided by height
in square meters.
Pathologic diagnosis was performed by percu-
taneous liver biopsies (n = 157), which were ana-
lyzed by pathologists unaware of the patients’
characteristics. Hepatic inflammation and fibrosis
were assessed according to the modified Knodell
histologic activity index (HAI).23 Steatosis was
scored according to the Metavir classification 
system as follows: 0, no steatosis; mild, involving
less than 10% of hepatocytes with steatosis; mod-
erate, 10% to 30% of hepatocytes affected; severe,
more than 30% of hepatocytes affected.24
During the same period, 165 age, sex and
BMI-matched healthy subjects were selected as
normal controls from the database of our gen-
eral health evaluation center. Fifty-five consecutive
chronic hepatitis B patients who were followed-
up regularly in our clinics and not receiving any
prior antiviral therapy were selected as etiologic
controls. The study was approved by the institu-
tional review board of the hospital, and informed
consent was obtained from the patients.
Among the 165 patients with chronic hepati-
tis C, 143 received 24 weeks of antiviral treatment
with standard dose regimens of PEG IFN alfa-2a
(180mcg/wk) or PEG IFN alfa-2b (1.5mcg/kg/wk)
and ribavirin (1000 mg/day if patient weight
< 75 kg, and 1200 mg/day if ≥ 75 kg), which 
followed recommendations from the Bureau of
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National Health Insurance in Taiwan.25 Serum
HCV RNA was assessed at the end of treatment
and 24 weeks after discontinuation of therapy.
Sustained virological response (SVR) was defined
as an undetectable serum HCV RNA at week 24
posttreatment. If this did not occur patients were
classified as non-SVR.
Laboratory investigations
Blood samples were obtained in the morning after
12 hours fasting and measured by the standard
laboratory technique. Plasma glucose, total cho-
lesterol and triglyceride were measured at base-
line, at the end of treatment, and at week 24 after
the end of treatment. Qualitative detection of HCV
RNA was performed by a standardized qualitative
reverse transcription-polymerase chain reaction
(RT-PCR) assay (Amplicor, Roche Diagnostics,
Branchburg, NJ, USA), using biotinylated primers
for the 5’ noncoding region. The lowest detec-
tion of the assay was 100 copies/mL. Genotyping
of HCV was performed using an HCV-Amplicor
reverse hybridization assay (Inno-LiPA™ HCV II;
Innogenetics N.V., Gent, Belgium).
Statistical analyses
Normally distributed or non-normally distributed
continuous variables were compared by Student
t test or the Mann-Whitney U test; while categor-
ical variables were compared using the χ2 test.
Comparisons among HBV, HCV subjects and
normal controls were performed using analysis of
variance with least significant difference post-hoc
correction between groups. Spearman’s correla-
tion coefficient analysis was used to assess the
significance of associations between variables
and serum total cholesterol or triglyceride levels.
Multiple linear regression analysis with stepwise
variable selection was performed to assess the inde-
pendent factors. Multivariate analysis with logis-
tic regression model was performed to determine
the independent factors associated with SVR. Paired
t test was preformed to compare the variables such
as total cholesterol, triglyceride and body weight
at baseline, at the end of treatment and at the end
of follow-up. All analyses were carried out using
SPSS software version 15.0 (SPSS Inc., Chicago,
IL, USA). All tests were 2-tailed, and a p value
< 0.05 was considered statistically significant.
Results
Table 1 shows the baseline characteristics of 165
enrolled HCV patients. Patients included 80 men
Table 1. Baseline characteristics of 165 patients
with chronic hepatitis C
Variables Mean ± SD or n (%)
Age (yr) 52.7 ± 11.1
Gender
Male 80 (48.5)
Female 85 (51.5)
Body mass index (kg/m2) 24.6 ± 3.6
DM 36 (21.8)
Sugar (mg/dL) 107 ± 36
Total cholesterol (mg/dL) 171 ± 31
Triglyceride (mg/dL) 105 ± 60
ALT (U/L) 166 ± 92
Platelet (104/μL) 17.9 ± 5.9
HCV genotyping
1 70 (42.4)
2 77 (46.7)
3 1 (0.6)
4 1 (0.6)
6 2 (1.2)
Unknown 14 (8.5)
HAI score (n = 157)
< 8 62 (39.5)
≥ 8 95 (60.5)
Fibrosis stage (n = 157)
F0 14 (8.9)
F1–2 79 (50.3)
F3, 4 64 (40.8)
Steatosis grade (n = 157)
Nil 91 (58.0)
Mild (0 to < 10%) 26 (16.5)
Moderate (≥ 10 to < 30%) 33 (21.0)
Severe (≥ 30%) 7 (4.5)
SD = standard deviation; DM = diabetes mellitus; ALT = alanine
aminotransferase; HCV=hepatitis C virus; HAI=histologic activity
index.
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and 85 women, with a mean age of 52.7 ± 11.1
years. BMI ranged from 16.4 kg/m2 to 36.9 kg/m2
with a mean of 24.6±3.6kg/m2. Thirty-six (21.8%)
patients had comorbid disease with diabetes mel-
litus (DM). Genotype 1 and 2 accounted for the
leading genotypes of HCV infection and the dis-
tribution showed that genotype 1 was present in
70 patients (42.4%), genotype 2 was present in
77 patients (46.7%), genotype 3 in 1 patient
(0.6%), genotype 4 also in 1 patient (0.6%), geno-
type 6 in 2 patients (1.2%) and unknown geno-
type occurred in 14 patients (8.5%). Of 156 biopsy
specimens, hepatic steatosis in liver tissue was
present in 66 subjects. Mild steatosis was seen in
26 patients (16.5%), moderate steatosis in 33
subjects (21%) and severe steatosis in 7 patients
(4.5%). Fibrosis was absent in 14 patients (8.9%),
stage 1 or 2 fibrosis was found in 79 patients
(50.3%), and stage 3 or 4 fibrosis was seen in 64
patients (40.8%).
Comparison of serum fasting sugar, total cho-
lesterol and triglyceride levels between chronic
hepatitis C patients and age, sex and BMI-matched
healthy controls or chronic hepatitis B patients
are shown in Table 2. The prevalence of DM was
higher (21.8%) in chronic hepatitis C patients
compared with normal controls (10.3%) or those
infected with HBV (9.1%; both p< 0.05). Patients
with HCV infection had significantly higher plasma
sugar and lower total cholesterol and triglyceride
levels than normal controls (p = 0.003, p < 0.001,
p < 0.001, respectively). Patients with HBV infec-
tion had significantly lower total cholesterol and
triglyceride levels than normal controls (p= 0.028,
p = 0.001, respectively). Serum total cholesterol
levels were lower in HCV patients than in those
infected with HBV (p < 0.001).
As shown in Table 3, factors associated with
baseline total cholesterol levels were DM (p =
0.04), BMI (p<0.001), triglyceride level (p<0.001)
and steatosis grade (p = 0.014). Male gender (p =
0.015), BMI (p<0.001), cholesterol level (p<0.001)
and steatosis grade (p = 0.011) correlated with se-
rum triglyceride levels. By stepwise multiple lin-
ear regression analysis, BMI, triglyceride and DM
were independent factors associated with serum
cholesterol levels. Male gender, cholesterol and
BMI were independent factors of serum triglyceride
levels.
Baseline variables contributing to SVR to PEG-
IFN plus ribavirin therapy in 143 chronic hepati-
tis C patients are summarized in Table 4. SVR was
obtained in 105 cases (73.4%). The predictors of
SVR were young age (p = 0.036), non-genotype 1
(p < 0.001), mild fibrosis stage (p < 0.001), low
serum cholesterol level (p = 0.01), high platelet
count (p= 0.031) and ALT level (p= 0.039) by uni-
variate analysis. Gender, DM, BMI, hepatic HAI
score, hepatic steatosis and serum triglyceride level
did not appear to affect the SVR rate. In stepwise
multiple logistic regression analysis, genotype 
2 or 3 [odds ratio (OR) 10.10, 95% confident 
Table 2. Comparison of sugar, total cholesterol and triglyceride levels between chronic hepatitis C patients
and healthy controls or chronic hepatitis B patients
HCV (n = 165) Normal control (n = 165) HBV (n = 55) p
Age (yr) 52.7 ± 11.1 52.0 ± 9.8 50.4 ± 11.0 NS
Gender (male/female) 85/80 85/80 22/33 NS
DM, n (%) 36 (21.8) 17 (10.3) 5 (9.1) 0.006a
Body mass index (kg/m2) 24.6 ± 3.7 24.8 ± 3.2 24.4 ± 3.7 NS
Sugar (mg/dL) 107 ± 36 97 ± 19 97 ± 30 0.005b
Total cholesterol (mg/dL) 171 ± 31 203 ± 34 191 ± 38 < 0.001a,c
Triglyceride (mg/dL) 105 ± 60 143 ± 99 101 ± 43 < 0.001b,c
ALT (U/L) 166 ± 92 29 ± 22 44 ± 60 < 0.01b,c
aSignificant differences between HCV subjects and normal control or HCV subjects and HBV patients; bsignificant differences between
HCV subjects and normal control; csignificant differences between HBV subjects and normal control. NS = not significant; HCV =
hepatitis C virus; HBV = hepatitis B virus; DM = diabetes mellitus; ALT = alanine aminotransferase.
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Table 3. Associated factors of serum cholesterol and triglyceride levels in 165 subjects with hepatitis C virus
Cholesterol Triglyceride
Spearman’s r p Spearman’s r p
Age 0.027 0.163 −0.106 0.178
Gender NA 0.209 NA 0.015
DM NA 0.04 NA 0.602
BMI 0.267 < 0.001 0.324 < 0.001
Sugar (mg/dL) 0.040 0.610 0.090 0.257
Total cholesterol (mg/dL) – – 0.292 < 0.001
Triglyceride (mg/dL) 0.292 < 0.001 – –
Platelet (104/μL) 0.089 0.261 0.119 0.133
ALT (U/L) 0.003 0.965 0.036 0.651
Genotype 1 NA 0.105 NA 0.052
HAI score −0.034 0.672 0.074 0.360
Fibrosis score −0.074 0.360 0.078 0.334
Steatosis grade 0.199 0.014 0.205 0.011
Body mass index (BMI), triglyceride and diabetes mellitus (DM) were independent factors associated with serum cholesterol levels by
stepwise multiple linear regression analysis. Male gender, cholesterol and BMI were independent factors of serum triglyceride levels.
NA = not applicable, Mann-Whitney U test. ALT = alanine aminotransferase; HAI = histologic activity index.
Table 4. Factors contributing to sustained viral response to peginterferon plus ribavirin therapy for chronic
hepatitis C patients
SVR Non-SVR p
Number of patients 105 38
Age (mean ± SD; yr) 51.7 ± 11.8 56.2 ± 8.9 0.036
Gender (male/female) 52/53 16/22 0.276
DM 18/87 8/30 0.378
BMI 24.3 ± 3.7 25.2 ± 4.0 0.228
Genotype 1 + 4 + 6/2 + 3 37/67 30/6 < 0.001
HAI score 8.1 ± 2.0 8.5 ± 1.8 0.192
Fibrosis (0–2/3, 4) 65/36 13/25 0.001
Steatosis (−/+) 44/56 15/23 0.388
Sugar (mg/dL) 105 ± 37 108 ± 36 0.681
Total cholesterol (mg/dL) 165 ± 30 179 ± 27 0.010
Triglyceride (mg/dL) 101 ± 47 107 ± 43 0.404
Platelet (104/cumm) 17.1 ± 5.4 14.8 ± 6.0 0.031
ALT (U/L) 178 ± 99 142 ± 64 0.039
Genotype and advanced fibrosis were significant variables by stepwise multiple logistic regression analysis. SVR = sustained virological
response; SD = standard deviation; DM = diabetes mellitus; BMI = body mass index; HAI = histologic activity index; ALT = alanine
aminotransferase.
Table 5. Stepwise multiple logistic regression analysis of factors associated with sustained viral response
Comparison OR 95% CI p
Genotype 2 + 3 vs. 1 + 4 + 6 10.10 3.106–33.33 < 0.001
Fibrosis 0–2 vs. 3,4 5.464 1.860–16.05 0.002
OR = Odds ratio; CI = confidence interval.
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incidence (CI) = 3.106–33.33, p< 0.001] and mild
hepatic fibrosis (F0-2; OR 5.464, 95% CI = 1.860–
16.05, p = 0.002) were independent factors asso-
ciated with SVR.
The figure shows the comparison of serial
changes of serum total cholesterol and triglyceride
levels and body weight between SVR and non-SVR
groups. In the SVR group, serum cholesterol level
was stationary from baseline (165 ± 30 mg/dL)
to the end of treatment (161 ± 29 mg/dL), but in-
creased to 191 ± 36 mg/dL at week 24 posttreat-
ment (p < 0.001). By contrast, no changes in
cholesterol values relative to baseline occurred in
non-SVR group (179±27 mg/dL at baseline, 172±
35 mg/dL at the end of treatment and 173 ±
25 mg/dL at week 24 posttreatment). Similarly,
serum triglyceride level increased from 100 ±
47 mg/dL at baseline to 128 ± 66 mg/dL at the
end of treatment (p < 0.001) and 116 ± 77 mg/dL
at week 24 posttreatment (p = 0.029) among SVR
patients, whereas the change of serum triglyc-
eride level was not significant in non-SVR sub-
jects. In both groups, BMI significantly decreased
at the end of treatment (p < 0.001), but returned
to baseline measurements at week 24 posttreat-
ment (p > 0.05).
Discussion
In the present study, we demonstrated that pa-
tients with chronic HCV infection had a higher
prevalence of DM and lower serum cholesterol
and triglyceride levels compared with age, sex and
BMI-matched healthy individuals. Consistent with
previous observations, our study confirms the sig-
nificant associations between HCV infection and
metabolic abnormalities, including glucose and
lipid turnover.7,9–11 Insulin resistance might ex-
plain the association between DM and HCV in-
fection, which was also observed in our previous
study.10 Recently, a large scale community-based
study in Taiwan showed both HBV and HCV in-
fection were independent factors associated with
lower serum cholesterol and triglyceride levels.11
Our present results further showed that serum
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Figure. Clinical evolution of serum total cholesterol (T-chol),
triglyceride levels and body mass index (BMI) during and
after treatment according to virological response: sustained
virological response (SVR) and non-SVR (NSVR). The paired
t test indicated statistical significance when baseline cho-
lesterol was compared with that at the end of follow-up 
in SVR patients (165 ± 30 mg/dL vs. 191 ± 36 mg/dL, p <
0.001). Baseline triglyceride level (100 ± 47 mg/dL) was
also lower than that at the end of treatment (12±66mg/dL,
p<0.001) and at the end of follow-up (116 ± 77 mg/dL,
p = 0.029) in SVR patients.
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total cholesterol level was lower in chronic hepa-
titis C patients than in those infected with HBV.
Whether there is a difference between lipid me-
tabolism and infection of HBV and HCV needs to
be further explored in future studies.
Although our work was not designed to clar-
ify the pathogenic mechanism between HCV and
lipid profile, a few hypotheses can be put forward.
The low-density lipoprotein (LDL) receptor was
reported to serve as a candidate receptor for HCV
endocytosis into the liver.12–14 Intracellular cho-
lesterol level could modulate the expression of
LDL receptors, hence, high LDL-cholesterol may
compete with the HCV particle and limit the
spread of HCV in hepatocytes.12,26 On the con-
trary, HCV itself may also impair lipid metabolism.
In particular, HCV particles could bind to a lipid
protein, such as cholesterol and triglyceride, via the
affinity outer capsule in the sera.13,14,27 These find-
ings suggest that HCV infection might be associ-
ated with lipid metabolism in terms of lower
serum cholesterol and triglyceride levels.11,13,14
Previous studies have proposed that higher
serum LDL and cholesterol levels at baseline may
be significant prognostic indicators for treatment
outcome in chronic hepatitis C patients receiving
IFN based therapy,18,19,28 but this finding has not
been supported by other reports.29,30 In our study,
patients who achieved SVR had lower serum total
cholesterol than those without SVR, as determined
by univariate analysis. However, this association
became insignificant based on stepwise multiple
logistic regression analysis, showing that geno-
type 2/3 and mild hepatic fibrosis were indepen-
dent factors associated with SVR, indicating the
presence of potential confounding effects. Ours
and other conflicting data might be associated
with the different cohorts of patient collection
and different treatment regimens (IFN or PEG-
IFN and/or ribavirin) as well as different study
designs (retrospective or prospective). Further large
scale randomized studies are necessary to clarify
this point.
It is worth noting that serum hypocholes-
terolemia and hypotriglyceridemia reversed sig-
nificantly after SVR to PEG-IFN plus ribavirin
therapy in chronic hepatitis C patients. In con-
trast, there was no evident change in the lipid
profile relative to baseline in the non-SVR group.
We speculated that these lipid changes were re-
lated to HCV eradication, which might decrease
the amount of HCV-bound lipid, thus increasing
the posttreatment serum lipid level in the SVR
patients. Also, these finding may be explained
through the similarities between HCV replication
and HMG-CoA reductase inhibitors effects on cho-
lesterol and LDL levels.28 Thus, successful elimi-
nation of HCV would be predicted to remove
these diversions, and result in a rebound of cir-
culating cholesterol and LDL levels. Another in-
teresting finding is that the triglyceride levels
were the highest at the end of treatment and de-
creased at the end of follow-up. This dramatic
change in serum triglyceride levels would be ex-
pected to be caused by the IFN treatment itself.
The activity of hepatic triglyceride lipase, an en-
zyme that degrades serum triglyceride, has been
reported to be inhibited during IFN administra-
tion, and hepatocellular triglyceride synthesis is
known to be stimulated by IFN treatment.31,32
Previous studies have reported that the im-
pact on the lipid profile and hepatic steatosis dif-
fered due to HCV genotype.9,33–37 In patients
infected by HCV genotype 3, steatosis is gener-
ally induced by the virus itself through a direct
cytopathic effect, while in those infected with
genotype 1, steatosis seems to be associated with
pre-existing risk factors for nonalcoholic fatty liver
disease.33,34 Serfaty et al showed that patients in-
fected with HCV genotype-3 had lower serum total
cholesterol levels than those with other geno-
types.9 Moreover, genotype-3 infection is rare in
East Asian countries, such as Japan and Taiwan,
where the majority of patients were infected by
genotype 1 or 2. In our study, we did not find a
difference in serum cholesterol and triglyceride
levels between genotype 1 and 2 patients. Further-
more, we showed that changes of serum lipid
levels were only related to the response to antiviral
therapy, and were not associated with the HCV
genotype (data not shown). However, a recent
study by Hsu et al showed that lipid profiles were
Y.H. Kuo, et al
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significantly associated with HCV viral load in
genotype 2, but not in genotype 1 infection in
Taiwan.34 Further studies are necessary to clarify
this point.
The major limitation of our study is that all
patients received a 24-week treatment course, irre-
spective of HCV genotype. Our treatment protocol
was adopted by the National Health Insurance
bureau in Taiwan according to the results of a
multi-center randomized trial, which showed a
satisfactory efficacy of a 24-week course of PEG-
IFN plus ribavirin therapy for Taiwanese pa-
tients.37 This might lead to undertreatment in
some genotype-1 patients, who needed longer
duration (48 weeks) to obtain a better response.
Beyond that, the detailed lipid profile, such as LDL-
cholesterol and high density lipid-cholesterol, as
well as the prevalence and specific features of the
metabolic syndrome, such as blood pressure and
waist circumference, were not obtained. It will be
interesting to determine the association of com-
plete lipid profile and metabolic syndrome with
the effect of anti-HCV treatment in further stud-
ies. Finally, lipid changes were studied up until 
6 months after the end of treatment, thus pro-
longed follow-up data are needed to clarify the
long-term impact of anti-HCV therapy on the 
reversal of lipid profile.
In conclusion, our study showed that patients
with chronic HCV infection had significantly lower
total cholesterol and triglyceride levels compared
with age, sex, and BMI-matched normal controls.
Successful eradication of HCV by PEG-IFN plus
ribavirin therapy is associated with the reversal
of hypolipidemia. Further investigations are nec-
essary to disclose the clinical outcomes of rebound
in serum lipid levels, such as the development of
coronary artery or cerebral vascular disease, among
SVR patients.
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